구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tiragolumab and Atezolizumab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Head and Neck Neoplasms; MSI-H Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | binds to the inhibitory immune checkpoint TIGIT (T-cell immunoreceptor |
MoA Biomarker | PD-L1-positive |
PK/PD Species | NHP, Macaque, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | PD |
Toxicology Species | NHP, Macaque, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | pneumonitis, cardiac arrest, gastrointestinal haemorrhage, hepatic failure, and bacterial p |
Clinical Safety signal | pneumonitis, cardiac arrest, gastrointestinal haemorrhage, hepatic failure, and bacterial p |
Clinical Selected reported efficacy | ORR 77.3% |
Clinical Reported ORR | 77.3% |
Clinical Reported PFS | 2.07 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT05116202 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT05116202 |
Preclinical Animal (cat.) | Mouse |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Tiragolumab and Atezolizumab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Head and Neck Neoplasms; MSI-H Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | binds to the inhibitory immune checkpoint TIGIT (T-cell immunoreceptor |
MoA Biomarker | PD-L1-positive |
PK/PD Species | NHP, Macaque, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
PK/PD Experiment | PD |
Toxicology Species | NHP, Macaque, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, Monkey, In vitro |
Toxicology Major finding | pneumonitis, cardiac arrest, gastrointestinal haemorrhage, hepatic failure, and bacterial p |
Clinical Safety signal | pneumonitis, cardiac arrest, gastrointestinal haemorrhage, hepatic failure, and bacterial p |
Clinical Selected reported efficacy | ORR 77.3% |
Clinical Reported ORR | 77.3% |
Clinical Reported PFS | 2.07 |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT05116202 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT05116202 |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교